文献速递眼底病与葡萄膜炎

VIEW 1和VIEW 2研究:固定剂量抗VEGF治疗52周后新生血管活动变化

Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies.
PubMed 文献 · Br J Ophthalmol · 2019-12-11

这项对III期VIEW 1和VIEW 2研究的整合事后分析纳入2373只新生血管性年龄相关性黄斑变性(nAMD)眼,接受固定剂量抗VEGF治疗。52周时,16.0%的眼仍存在渗漏和视网膜积液,无渗漏和积液的眼最佳矫正视力(BCVA)增益数值上更高(10.3 vs 9.2字母)。

要点

  • 52周时无渗漏和积液的眼BCVA增益数值上高于仍有渗漏和积液的眼。
  • 基线 predominantly classic(PC)病变的眼52周时渗漏和积液比例低于 occult 病变(11.6% vs 20.1%)。

核心结论

  • 固定剂量抗VEGF治疗52周可使大多数nAMD眼疾病活动消失(无渗漏和积液)。
  • 抗VEGF治疗对渗漏/积液状态的影响在 predominantly classic(PC)病变中优于 occult 病变。

研究设计与样本

  • III期VIEW 1(NCT00509795)和VIEW 2(NCT00637377)研究的整合事后分析,纳入2373只nAMD眼。
  • 眼接受玻璃体腔内阿柏西普或雷珠单抗治疗,独立 masked 阅读中心在基线、第24周和第52周评估渗漏(荧光素血管造影)和视网膜积液(光学相干断层扫描)。
  • 分析评估了渗漏/积液状态与最佳矫正视力(BCVA)的关系,并评价基线病变类型(predominantly classic(PC)、minimally classic(MC)、occult)的影响。
  • 所有治疗组数据合并分析。

主要发现

  • 基线时95.4%的眼同时存在渗漏和积液。
  • 第52周时,16.0%的眼存在渗漏和积液。
  • 第52周时,无渗漏和积液的眼平均BCVA增益数值上大于有渗漏和积液的眼(10.3 vs 9.2字母)。
  • 第52周时,PC、MC和occult病变眼分别有11.6%、15.3%和20.1%存在渗漏和积液。

临床怎么用

  • 固定剂量抗VEGF治疗52周可使大多数nAMD眼达到无渗漏和积液的疾病活动消失状态。
  • 治疗中监测渗漏和积液状态有助于评估疾病活动,PC病变对治疗的反应可能优于occult病变。

局限性

  • 本研究为事后分析,所有治疗组数据合并,可能影响结果的解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To understand changes in disease activity as assessed by leakage and retinal fluid status in patients with neovascular age-related macular degeneration (nAMD) receiving fixed dosing with an anti-vascular endothelial growth factor (anti-VEGF) agent. METHODS: In the phase III VIEW 1 (NCT00509795) and VIEW 2 (NCT00637377) studies, eyes with nAMD were treated with intravitreal aflibercept or ranibizumab. Independent, masked reading centres determined the presence/absence of leakage (fluorescein angiography) and retinal fluid (optical coherence tomography) at baseline, week 24 and week 52. In this integrated, post hoc analysis of the VIEW studies, the relationship between leakage/fluid status and best-corrected visual acuity (BCVA) was assessed. The impact of baseline lesion type (predominantly classic (PC), minimally classic (MC), occult) was also evaluated. Data from all treatment groups were pooled. RESULTS: 2373 eyes were included in this analysis. At baseline, 95.4% of eyes presented with both leakage and fluid. By week 52, leakage and fluid were present in 16.0% of eyes. Mean BCVA gains at week 52 were numerically greater in eyes without leakage and fluid versus eyes with both leakage and fluid (10.3 vs 9.2 letters). At week 52, 11.6%, 15.3% and 20.1% of eyes with PC, MC and occult lesions, respectively, had both leakage and fluid present. CONCLUSION: In this post hoc analysis, fixed dosing with an anti-VEGF agent over 52 weeks eliminated disease activity (absence of both leakage and fluid) in most eyes. The effect of anti-VEGF treatment on leakage/fluid status favoured PC versus occult lesions.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Moshfeghi DM, Thompson D, Saroj N, et al. Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies. Br J Ophthalmol. 2019. PMID: 31826853. doi:10.1136/bjophthalmol-2019-315021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。